Head to head comparison of two commercial fecal calprotectin kits as predictor of Mayo endoscopic sub-score and mucosal TNF expression in ulcerative colitis

Rasmus Goll1,2*, Richard Heitmann3, Øystein Kittel Moe2, Katrine Carlsen4, Jon Florholmen1,2

1 Institute of Clinical Medicine, UiT the Arctic University of Norway, Tromsø, Norway, 2 Medical Gastroenterology, Division of Internal medicine, University Hospital of North Norway, Tromsø, Norway, 3 Department of Gastroenterology, Telemark Hospital, Skien, Norway, 4 Department of Pediatrics, Hvidovre University Hospital, Copenhagen, Denmark

* rasmus.goll@uit.no

Abstract

Background

Fecal calprotectin is widely used to monitor disease activity in patients with inflammatory bowel disease. Multiple commercial kits exist, however, since the analyses are not standardized, these kits cannot be used interchangeably. We aimed to perform a technical evaluation of two kits (Calpro from Calprolab, Norway and Calprest from Eurospital, Italy) and perform a tuning for detection of clinically relevant disease states in ulcerative colitis.

Materials and methods

For tuning against different clinical states a total of 116 patients with ulcerative colitis were recruited (67 of which were part of an earlier publication). For the technical evaluation an additional series of 80 random samples from the hospital lab were included. Technical evaluation was done by correlation and limits of agreement analysis; cut-off levels were explored by ROC analysis against clinically relevant actual states.

Results

The technical evaluation revealed good correlation between assays, however a non-linear difference was found: At values below 200 mg/kg, no significant bias was found; in the interval 200–1000 mg/kg the Calprest assay measured on average 30% lower than Calpro; and at higher values Calprest measured 60% higher values than Calpro. Both assays predicted Mayo endoscopic score (MES) 0 (cutoff 28: sensitivity 0.38; specificity 0.82 for Calprest; cutoff 28: sensitivity 0.50; specificity 0.77 for Calpro), and MES 2–3 (cutoff 148: sensitivity 0.72; specificity 0.80 for Calprest; cutoff 208: sensitivity 0.64; specificity 0.80 for Calpro), but did not predict normalization of mucosal TNF transcript per se. A combination of calprotectin

PLOS ONE | https://doi.org/10.1371/journal.pone.0224895 December 2, 2019 1 / 12
and MES predicted mucosal TNF transcript values reasonably well (Calpro: sensitivity 0.85, specificity 0.58; Calprest: sensitivity 0.85, specificity 0.61).

Conclusion
The Calpro and Calprest assays correlated well, but subtle differences were found, underlining the need for kit-specific cut-off values. Both kits were most precise in predicting active inflammation (MES 2–3), but less so for prediction of mucosal healing (MES 0) and normalization of mucosal TNF gene expression.

Introduction
Assessment of disease activity in ulcerative colitis (UC) pose several problems as there is often a discordance between patient reported symptom burden and actual state of the colon mucosa [1]. Fecal calprotectin has become an important non-invasive biomarker for surveillance of inflammatory activity in inflammatory bowel disease. To some extent, the daily clinical decisions can be made based on this analysis [2]. The overall target for the treatment of UC should be resolution of inflammation as mounting evidence indicate improved prognosis for patients who achieve deep remission (i.e. healing of mucosa) [3,4]. The state of deep remission decreases risk of long term complications and necessity for surgery [5]. In clinical practice the finding of Mayo endoscopic subscore (MES) 0–1 is considered “endoscopic remission” [3]. Recent data, however, indicates that MES 1 is not completely normal with regards to inflammatory histological state [6]. This increases the risk of relapse [7] and later complications. To achieve complete inflammatory remission, the aim should be MES 0. Another method to evaluate the activation state of the mucosal immune system is to quantify the Tumor Necrosis Factor (TNF) gene activity by tissue qPCR [8] from colon biopsies.

Several publications have aimed to assess fecal calprotectin measurements towards prediction of endoscopic findings [9–11]. There are however discrepancies between recommended cut-off values, which probably depend on technical differences between kits, as the method is not standardized. The availability of different commercial kits raises concern that cut-off values are not universal, but kit-specific. The focus of the present paper is to compare the performance of two commercial calprotectin ELISA kits: Calpro (Calprolab, Norway) and Calprest (Eurospital, Italy), and perform a tuning for detection of clinically relevant states of UC.

Materials and methods
Approval by the North Norwegian Regional Committee of Medical Ethics was granted (2012/1349). All study participants received information of the study and signed a consent form. Sixty-six participants with UC were recruited for an earlier publication [12] as part of a prospective project at the Department of Gastroenterology, University hospital of North Norway; additionally, 50 subjects with UC and 16 normal controls were recruited for the present study (please see Fig 1 and Table 1 for details). The participants were asked to deliver two separate fecal samples taken on different days during the week before endoscopy. At endoscopy participants were scored according to MES and samples for tissue qPCR were collected.

Due to missing values the actual number of observations in each analysis vary (Table 1). For day-to-day variation, dual samples were available from 51 individuals, obtained within 1
week (43 of these were part of the previous publication [12]). These dual samples were measured on both kits, and the variation between results analysed.

For head to head comparison of the two ELISA assays, the UC and normal control samples mentioned above were used. In addition, 80 samples from the routine calprotectin workflow at the hospital lab were picked at random, extracted, and analysed on both assays. These samples were only used for technical evaluation; thus no clinical information was obtained. For the most part those samples would be from IBD patients (both UC and Crohn’s disease), or samples used for diagnostic work-up in cases of chronic diarrhoea.

For 104 of the UC samples, MES were also available, which were used for ROC curves (67 of these observations were part of a previously published paper [12]). For 96 patients, a combination of TNF and calprotectin and MES values were available.

Both kits contain extraction devices for accurate sampling of the desired amount of fecal matter. The samples were mixed and extracted according to the manufacturer’s instructions for Calpro (Calprolab, Norway) and Calprest (Eurospital, Italy). The extracts were analysed on an automated system (Dynex DS2 ELISA processor, Dynex, Germany).
The method for TNF measurements have been published earlier [13]–in brief: biopsies were immediately immersed in RNA-later (Qiagen, Hilden, Germany) for storage. The biopsies were then disintegrated using a Magnalyzer (Roche, Germany) ceramic bead shaker system and RNA was isolated using the Allprep DNA/RNA Mini Kit (Qiagen) on a Qiacube instrument (Qiagen). Quantity and purity of the extracted RNA were determined using the Qubit 3 Fluorometer (Thermo Fisher Scientific, Waltham, MA, USA). cDNA was then produced with QuantiTect Reverse Transcription Kit (Qiagen), and qPCR was run using TaqMan assays for TNF with ACTB as housekeeping gene (previously published [13]; primers/probes ordered from Eurogentec, Liège, Belgium; Mastermix QuantiNova Probe RT-PCR Kit from Qiagen). Absolute quantification was done by a standard curve, based on a diluted PCR product. The cut-off value for normalisation is defined by the 95% upper CI limit for healthy controls.

Statistics

Samples with readings above the standard curves were set at limit (2000 mg/kg for Calpro and 3000 mg/kg for Calprest). Day-to-day variation and head-to-head comparison was performed by Pearson correlation and Bland-Altman limits of agreement analysis on raw data and In-transformed values. For single predictor, Receiver operating characteristic analysis (ROC), the raw data was used. A combined predictor of [MES + calprotectin] was constructed. To give the two base variables equal weight, both were standardized: [MES+calprotectin] = [MES/max MES] + [ln(calprotectin)/ln(max calprotectin*)]; for each assay (* defined by the standard curve for each assay). These constructed variables span values from 0 to 2. Optimal cut-off was defined by maximal Youden J. Statistical analysis was performed in IBM SPSS Statistics for Windows, Version 25.0. Armonk, NY, USA. Plots were produced in GraphPad Prism version 7.05 for Windows (GraphPad Software, La Jolla, CA, USA).

Results

Inter-assay variation

51 dual samples were extracted and analysed on both assays. Samples were collected within 1 week, but not on the same day. Both assays showed a fair correlation between the two samples with Pearson r = 0.744; P < 0.0001 for Calpro, and Pearson r = 0.729 P < 0.0001 for Calpro
(logarithmic transformation applied, please see Fig 2A and 2B). Bland-Altman plots showed that the variance of both assays were evenly distributed with no clinically relevant bias and a fairly equal limit of agreement (Fig 2C and 2D). These variations cover the total variance from sampling on different days, sample handling, extraction, and the ELISA method itself.

**Method comparison**

For direct comparison of the two assays, 186 samples from different individuals were extracted and the same extract was run using both ELISA assays. A direct correlation plot shows a
systematic skewing towards higher measurements in the high end using the Calprest kit. This reflects that the standard curve for Calprest extends to 3000, while Calpro stops at 2000. Thus a higher dynamic for the most elevated calprotectin values is expected using the Calprest assay (Fig 3A). Using log-transformed values, a good correlation can be seen (Fig 3B).

A Bland-Altman plot shows a tendency of lower mid-range values for the Calprest compared to the Calpro values (Fig 4A and 4B). This plot also shows that the range can be divided into sections: values of 0–200; 201–1000; and above 1000 (Fig 4C). Mean bias between the methods can be calculated as follows: segment 0–200: Calprest measures 3.9% lower than Calpro (transformed mean bias -0.04); 201–1000: Calprest measures 30% lower than Calpro (transformed mean bias -0.36); above 1000: too few datapoints, and the difference in maximal scale value makes Bland Altman analysis difficult to interpret in this segment. Calprest measures values 60% higher than Calpro (transformed mean bias of 0.47).

**ROC analysis**

For ROC analysis 104 observations were available for the MES, and 96 for the TNF gene expression measurement. A ROC curve for prediction of deep remission defined by MES of 0 is shown in Fig 5A; Both assays had a significant AUC: 0.73 (0.63–0.82; P < 0.0005) for Calpro, and 0.73 (0.64–0.83; P<0.0005) for Calprest, respectively. The Calprest kit may be marginally better at predicting MES 0 (Youden J 0.45; cut-off 100; sensitivity 0.86; specificity 0.60) vs Calpro (Youden J 0.41; cut-off 98; sensitivity 0.83; specificity 0.58). For both methods, however, a relatively low specificity is noted, and using these cut-off values may yield a considerable part of endoscopies with MES 1. However, for higher specificity, a cut-off of 28 is recommended for both kits (Calprest: specificity 0.82, sensitivity 0.38; Calpro: specificity 0.77, sensitivity 0.50).
A ROC curve for prediction of significant inflammation, defined by MES of 2–3, is shown in Fig 5B. Both assays again have significant AUC’s: 0.79 (0.70–0.89; P < 0.0005) for Calpro, and 0.80 (0.70–0.90; P < 0.0005) for Calprest. Optimal cut-off by maximal Youden J: 138 (J = 0.48; sensitivity = 0.72; specificity = 0.76) for Calpro, and 73 (J = 0.53; sensitivity = 0.88; specificity = 0.65) for Calprest. Cut-off for specificity 0.80: 208 (J = 0.44; sensitivity = 0.64; specificity = 0.80) for Calpro and 148 (J = 0.52; sensitivity = 0.72; specificity = 0.80) for Calprest.

We also tested if mucosal TNF gene expression could be predicted by fecal calprotectin. Using earlier defined cut-off for normal TNF gene expression of <7500 copies/ug total RNA, the samples were categorized as normal or high. We then entered this as actual state variable in a ROC curve for both assays (Fig 5C). The curves did not yield significant AUC’s: 0.58 (0.46–0.69; P = 0.24) for Calpro, and 0.57 (0.46–0.68; P = 0.29) for Calprest.

Finally, we tested a combination of MES and calprotectin (Fig 5D) For Calpro combined with MES, AUC was 0.72 (0.62–0.82; P = 0.001); for Calprest combined with MES the AUC was 0.71 (0.61–0.81; P = 0.001). Optimal cut-off by max Youden J was 0.81 for [MES+Calpro] (J = 0.43; sensitivity = 0.85; specificity = 0.58); and 0.79 for [MES+Calprest] (J = 0.46;
sensitivity = 0.85; specificity = 0.61). For specificity of 0.80, a cut-off of 0.51 for [MES+Calpro] (J = 0.13; sensitivity 0.33; specificity = 0.80); and a cut-off of 0.51 for [MES+Calprest] (J = 0.24; sensitivity 0.44; specificity 0.80) were found.

Fig 5. ROC curves. Prediction of endoscopic inflammatory activity. Panel A: Mucosal healing defined by Mayo endoscopic subscore (MES) = 0 by calprotectin (actual state: positives 42; negatives 62). Panel B: Significant inflammatory activity defined by MES 2–3 by calprotectin (actual state: positives 25; negatives 79). Panel C: Normalized mucosal TNF gene expression (<7500 copies/ug total RNA) by calprotectin (actual state: positives 27; negatives 69). Panel D: Normalized TNF gene expression (<7500 copies/ug total RNA) by the sum of calprotectin and MES (both standardized by ln transformation and division with the maximal scale value). For all plots: blue curve for Calprest; red curve for Calpro.
Discussion

We have performed an inter-assay variation analysis and head-to-head comparison of two commercial calprotectin kits, and explored cut-off values for MES 0, MES 2–3, and mucosal TNF transcript—features that are important to assess in follow-up of UC patients. The kits both performed well but the optimal cut-off values varied somewhat, and must be determined for each manufacturer. Additionally, subtle differences were detected both in linearity and level, which probably rely on differences in standards and/or antibodies provided in the kits. It is possible to predict MES 0 to a certain extent, but calprotectin cannot yield both high sensitivity and specificity with the same cut-off. Eventually, calprotectin can be used to select patients for endoscopic evaluation to confirm MES 0. The calprotectin tests alone could not predict normalization of mucosal TNF expression, but by adding MES, the combined variables performed better in predicting mucosal TNF normalization, however still at quite low performances when using cut-off for high specificity (Youden 0.13 and 0.24 for Calpro and Calprest, respectively). Direct measurement of TNF expression still remains necessary for evaluation of immunological remission.

Day to day variation in calprotectin measurements is illustrated by the spread in Fig 2A and 2B. This is in agreement with earlier reports investigating repeated sampling and other factors, like time of day and different extraction devices [14,15]. The much lower error reported in similar studies is not comparable since the same samples were measured twice, and thus only reflect technical intra-assay error [16,17]. Since fecal samples mostly are collected by the patient, factors regarding collection are difficult to standardize. Serial samples (at least 2) will increase reliability. In our practice, two consecutive normal calprotectin measurements prompt endoscopy to ensure full remission. This approach saves endoscopy resources while still enabling close follow-up.

Comparison between values obtained from same samples on the two kits revealed a non-linear relationship. At values below 200 mg/kg, no significant systematic bias was detected, but mid-range values 200–1000 mg/kg are on average 30% lower in the Calprest assay compared to the Calpro assay. The lack of standardization prevent evaluation of which is more “right” [2]. The higher values measured by Calprest in samples above 1000 mg/kg is probably a consequence of a higher dynamic range for Caprest because of assay and standard curve differences. Compared to similar studies, the differences between Calpro and Calprest are relatively minute [17–19]. In comparison the Calpro assay performed quite similar but slightly superior to the HK325 (Hycultbiotech, Netherlands), and the EK-CAL ELISA (Bühlmann Laboratories AG, Switzerland) [20].

Our suggested cut-off for MES 0 is comparable to the findings of Kristensen et al [21] but considerably lower than that suggested for other assays [10] which underlines the necessity of kit-specific cut-off level. Interestingly, our earlier publication using mean of two samples yielded a better AUC for MES 0, and slightly different cut-off values for the Calpro kit [12]; this likely reflect that dual sampling yield better precision in a system with high day to day variation.

Detection of significant inflammation (MES 2–3), on the other hand, shows different cut-off levels reflecting the difference in detected values by the assays. Moreover, the difference in standard curves especially affect the mid-high range samples which show higher dynamic in the Calprest assay. This underlines the necessity of kit-specific cut-off values. A similar conclusion must be drawn from similar studies demonstrating highly different cut-off values [17,18,22].

The level of mucosal TNF transcript was poorly predicted by calprotectin values. It has been shown earlier that even in endoscopically normalised mucosa, not all patients have
normalised TNF transcript level [8]. Combined with MES, however, the ROC analysis showed improvement, though not at a level that can stand alone as evaluation of immunological remission. Most likely, this represents a deeper level of remission, and, so far, the only way to assess this feature is by measuring TNF directly in biopsies.

Weaknesses of the study are primarily that the endoscopic evaluation was not done by central reader, but graded by different clinicians. Moreover, a relatively low number of samples were used in the inter-assay evaluation (n = 51); however, the plots illustrate the high day to day variation, and the importance of repeated samples still stands. Regarding the ROC curves, the number of observations are reasonable, however not high enough to validate the proposed cut-off values by e.g. split-half analysis. The main point being that cut-off values are kit-specific still stands, though.

Conclusions
In spite of a high day-today variation, calprotectin remains one of the best non-invasive measures of the inflammatory state in ulcerative colitis. However, even between these two highly correlated ELISA kits for calprotectin there are important differences, also in the interval containing cut-off values for clinical decisions. Consequently, due to the lack of standardisation for calprotectin measurement, cut-off values should be regarded as kit-specific. Both kits were most precise in predicting active inflammation (MES 2–3), but less so for prediction of mucosal healing (MES 0) and normalization of mucosal TNF gene expression. The Calprest assay has a higher dynamic range, the use of which is still to be determined. Calprotectin alone could not predict mucosal TNF transcript normalization.

Supporting information
S1 File. Raw data and metadata is available in SPSS format.
(SAV)

Acknowledgments
We thank Marian Remijn for expert technical assistance.

Author Contributions
Conceptualization: Rasmus Goll, Katrine Carlsen, Jon Florholmen.
Data curation: Rasmus Goll.
Formal analysis: Rasmus Goll, Katrine Carlsen.
Resources: Rasmus Goll, Richard Heitmann, Øystein Kittel Moe, Katrine Carlsen, Jon Florholmen.
Visualization: Rasmus Goll.
Writing – original draft: Rasmus Goll, Richard Heitmann.
Writing – review & editing: Richard Heitmann, Øystein Kittel Moe, Katrine Carlsen, Jon Florholmen.

References
1. Colombel J-F, Keir ME, Scherl A, Zhao R, de Hertogh G, Faubion WA, et al. Discrepancies between patient-reported outcomes, and endoscopic and histological appearance in UC. Gut. 2017; 66: 2063–2068. https://doi.org/10.1136/gutjnl-2016-312307 PMID: 27590995
2. Reenaers C, Bossuyt P, Hindryckx P, Vanpoucke H, Cremer A, Baert F. Expert opinion for use of faecal calprotectin in diagnosis and monitoring of inflammatory bowel disease in daily clinical practice. United Eur Gastroenterol J. 2018; 6: 1117–1125. https://doi.org/10.1177/205640618748046 PMID: 30288273

3. Römkens TEH, Gijsbers K, Kievit W, Hoentjen F, Drenth JPH. Treatment Targets in Inflammatory Bowel Disease: Current Status in Daily Practice. J Gastrointestin Liver Dis. 2016; 25: 465–471. https://doi.org/10.1543/jld.2014.1121.254.ken PMID: 27981302

4. Peyrin-Biroulet L, Ferrante M, Magro F, Campbell S, Franchimont D, Fidder H, et al. Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis. 2011; 5: 477–83. https://doi.org/10.1016/j.crohns.2011.06.009 PMID: 21939925

5. Macaluso FS, Cavallaro F, Felice C, Mazza M, Armuzzi A, Gionchetti P, et al. Risk factors and timing for colectomy in chronically active refractory ulcerative colitis: A systematic review. Dig Liver Dis. 2019; 1–8. https://doi.org/10.1016/j.dld.2018.10.001

6. Kanazawa M, Takahashi F, Tominaga K, Abe K, Izawa N, Fukushi K, et al. Relationship between endoscopic mucosal healing and histologic inflammation during remission maintenance phase in ulcerative colitis: a retrospective study. Endosc Int Open. 2019; 07: E568–E575. https://doi.org/10.1055/a-0869-7619 PMID: 30957007

7. Lobatón T, Bessissov T, Ruiz-Cerulla A, De Hertogh G, Bisschops R, Guardiola J, et al. Prognostic value of histological activity in patients with ulcerative colitis in deep remission: A prospective multicenter study. United Eur Gastroenterol J. 2018; 6: 765–772. https://doi.org/10.1177/205640617752207 PMID: 30083339

8. Olesen T, Rismo R, Gundersen MD, Paulsen EJ, Johnsen K, Kvamme J-M, et al. Normalization of mucosal tumor necrosis factor-α: A new criterion for discontinuing infliximab therapy in ulcerative colitis. Cytokine. 2016; 79: 90–5. https://doi.org/10.1016/j.cyto.2015.12.021 PMID: 26775117

9. Mak WY, Buisson A, Andersen MJ, Lei D, Pekow J, Cohen RD, et al. Fecal Calprotectin in Assessing Endoscopic and Histological Remission in Patients with Ulcerative Colitis. Dig Dis Sci. 2018; 63: 1294–1301. https://doi.org/10.1007/s10620-018-4980-0 PMID: 29468374

10. Lee S-H, Kim M-J, Chang K, Song EM, Hwang SW, Park SH, et al. Fecal calprotectin predicts complete mucosal healing and better correlates with the ulcerative colitis endoscopic index of severity than with the Mayo endoscopic subscore in patients with ulcerative colitis. BMC Gastroenterol. 2017; 17: 110. https://doi.org/10.1186/s12876-017-0669-7 PMID: 29061121

11. Theede K, Holck S, Ibsen P, Ladelund S, Nordgaard-Lassen I, Nielsen AM. Level of Fecal Calprotectin Correlates With Endoscopic and Histologic Inflammation and Identifies Patients With Mucosal Healing in Ulcerative Colitis. Clin Gastroenterol Hepatol. 2015; 13: 1929–36.e1. https://doi.org/10.1016/j.cgh.2015.05.038 PMID: 26051392

12. Carlsen K, Riis LB, Eidelberg H, Maagaard L, Thorkilaard T, Serbye SW, et al. The sensitivity of fecal calprotectin in predicting deep remission in ulcerative colitis. Scand J Gastroenterol. 2018; 53: 825–830. https://doi.org/10.1080/00365521.2018.1482956 PMID: 29968483

13. Diab J, Al-Mahdi R, Gouveia-Figueira S, Hansen T, Jensen E, Goll R, et al. A Quantitative Analysis of Colonic Mucosal Oxylipins and Endocannabinoids in Treatment-Naïve and Deep Remission Ulcerative Colitis Patients and the Potential Link With Cytokine Gene Expression. Inflamm Bowel Dis. 2019; 25: 490–497. https://doi.org/10.1093/ibd/izy349 PMID: 30476077

14. Kristensen V, Malmstrøm GH, Skar V, Raseth A, Mour M. Clinical importance of faecal calprotectin variability in inflammatory bowel disease: intra-individual variability and standardisation of sampling procedure. Scand J Gastroenterol. 2016; 51: 548–555. https://doi.org/10.3109/0309365521.2015.1117650 PMID: 26634305

15. Calafat M, Cabrè E, Mañosa M, Lobatón T, Marín L, Domènech E. High within-day variability of fecal calprotectin levels in patients with active ulcerative colitis: What is the best timing for stool sampling? Inflamm Bowel Dis. 2015; 21: 1072–1076. https://doi.org/10.1097/MIB.0000000000000349 PMID: 25793326

16. Oyaert M, Trouvé C, Baert F, De Smet D, Langlois M, Vanpoucke H. Comparison of two immunoassays for measurement of faecal calprotectin in detection of inflammatory bowel disease: (pre)-analytical and diagnostic performance characteristics. Clin Chem Lab Med. 2014; 52: 391–397. https://doi.org/10.1515/cclm-2013-0699 PMID: 24114912

17. Oyaert M, Boel A, Jacobs J, Van Den Bremt S, De Sloovere M, Vanpoucke H, et al. Analytical performance and diagnostic accuracy of six different faecal calprotectin assays in inflammatory bowel disease. Clin Chem Lab Med. 2017; 55: 1564–1573. https://doi.org/10.1515/cclm-2016-1012 PMID: 28222018
18. De Sloovere MMW, De Smet D, Baert FJ, Debrabandere J, Vanpoucke HJM. Analytical and diagnostic performance of two automated fecal calprotectin immunoassays for detection of inflammatory bowel disease. Clin Chem Lab Med. 2017; 55: 1435–1446. https://doi.org/10.1515/cclm-2016-0796 PMID: 28076305

19. Haisma S-M, Galaurchi A, Almahwzi S, Adekanmi Balogun JA, Muller Kobold AC, van Rheenen PF. Head-to-head comparison of three stool calprotectin tests for home use. Szecsi PB, editor. PLoS One. 2019; 14: e0214751. https://doi.org/10.1371/journal.pone.0214751 PMID: 30998692

20. Mirsepasi-Lauridsen HC, Holmetoft UB, Halkjaer SI, Krogfelt KA, Petersen AM. Comparison of three commercial fecal calprotectin ELISA test kits used in patients with Inflammatory Bowel Disease. Scand J Gastroenterol. 2016; 51: 211–7. https://doi.org/10.3109/00365521.2015.1081399 PMID: 26359672

21. Kristensen V, Klepp P, Cvancarova M, Reseth A, Skar V, Moum B. Prediction of endoscopic disease activity in ulcerative colitis by two different assays for fecal calprotectin. J Crohns Colitis. 2015; 9: 164–9. https://doi.org/10.1093/ecco-jcc/jju015 PMID: 25518057

22. Acevedo D, Salvador MP, Girbes J, Estan N. Fecal Calprotectin: A Comparison of Two Commercial Enzymoimmunoassays and Study of Fecal Extract Stability at Room Temperature. J Clin Med Res. 2018; 10: 396–404. https://doi.org/10.14740/jocmr3275e PMID: 29581802